DDInter927 DDInter864
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).
Histrelin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Histrelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risperidone
Histrelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Histrelin {u} may lead to a major life threatening interaction when taken with {v} Arsenic trioxide
Histrelin {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Histrelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Histrelin may lead to a major life threatening interaction when taken with Arsenic trioxide
Histrelin may lead to a major life threatening interaction when taken with Lefamulin